EVC
RVNC

Eidelman Virant Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Eidelman Virant Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,450
Closed -$239K – 209
2020
Q4 		$239K Buy
+8,450
New +$219K 0.1% 134

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Eidelman Virant Capital's RVNC Position: Q1 2021 in Review

Eidelman Virant Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2021, closing a stake of 8,450 shares — an estimated $239K sold.

Eidelman Virant Capital first reported a position in RVNC in Q4 2020 and held it in 1 quarter. The position peaked at $239K in Q4 2020. 149 funds tracked by Wall St. Rank hold RVNC as of Q1 2021.

  • Eidelman Virant Capital reported no remaining Revance Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Eidelman Virant Capital sold 8,450 Revance Therapeutics, Inc. shares in Q1 2021, an estimated $239K.
  • Eidelman Virant Capital first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 1 quarter.
  • Eidelman Virant Capital's Revance Therapeutics, Inc. position peaked at $239K in Q4 2020.
  • 149 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2021.

Based on Eidelman Virant Capital's 13F filing for Q1 2021, filed 20 Apr 2021.